February 14, 2017 News by Patricia Silva, PhD Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds EMD SorenoĀ has recently published Phase 3 clinical data showing that CladribineĀ tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared toĀ placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, āReduced brain atrophy rates are associated with lower risk of disability progression…
September 19, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Data on Merck Treatment for Relapsing MS, Cladribine Tablets, Show Long-Term Benefit MerckĀ recently presented new efficacy data from itsĀ three Phase 3 clinical trials, showing that a relatively short course of treatment withĀ Cladribine tabletsĀ led to long-term reductions in annualized relapse rate (ARR) in people with relapsing multiple sclerosis (RMS). The data were givenĀ in two oral presentationĀ at the 32nd Congress of the…
July 20, 2016 News by Patricia Silva, PhD Merck KGaA’s Investigational MS Therapy Cladribine Gets EMA Marketing Authorization Application Review Merck KGaA, Darmstadt, GermanyĀ recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the company’sĀ investigational productĀ Cladribine Tablets as a therapy forĀ relapsing multiple sclerosis (RMS) in Europe. Cladribine is a synthetic antineoplastic agent able to suppress the immune system, causing relatively few…
October 9, 2015 News by Patricia Silva, PhD Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…
September 14, 2015 News by Patricia Silva, PhD Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy MerckĀ recently reported its intention to file for European registration of its product candidate forĀ relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the immune system. Cladribine causesĀ relatively few side effects and results in very little non-target cell loss. Merck’s decision follows new findingsĀ and further characterization of…